Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

491 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The Clinical and Genetic Landscape of Hereditary Cancer: Experience from a Single Clinical Diagnostic Laboratory.
Tsoulos N, Agiannitopoulos K, Potska K, Katseli A, Ntogka C, Pepe G, Bouzarelou D, Papathanasiou A, Grigoriadis D, Tsaousis GN, Gogas H, Troupis T, Papazisis K, Natsiopoulos I, Venizelos V, Amarantidis K, Giassas S, Papadimitriou C, Fountzilas E, Stathoulopoulou M, Koumarianou A, Xepapadakis G, Blidaru A, Zob D, Voinea O, Özdoğan M, Ergören MÇ, Hegmane A, Papadopoulou E, Nasioulas G, Markopoulos C. Tsoulos N, et al. Among authors: papadimitriou c. Cancer Genomics Proteomics. 2024 Sep-Oct;21(5):448-463. doi: 10.21873/cgp.20463. Cancer Genomics Proteomics. 2024. PMID: 39191493 Free PMC article.
Copy Number Variations (CNVs) Account for 10.8% of Pathogenic Variants in Patients Referred for Hereditary Cancer Testing.
Agiannitopoulos K, Pepe G, Tsaousis GN, Potska K, Bouzarelou D, Katseli A, Ntogka C, Meintani A, Tsoulos N, Giassas S, Venizelos V, Markopoulos C, Iosifidou R, Karageorgopoulou S, Christodoulou C, Natsiopoulos I, Papazisis K, Vasilaki-Antonatou M, Kabletsas E, Psyrri A, Ziogas D, Lalla E, Koumarianou A, Anastasakou K, Papadimitriou C, Ozmen V, Tansan S, Kaban K, Ozatli T, Eniu DT, Chiorean A, Blidaru A, Rinsma M, Papadopoulou E, Nasioulas G. Agiannitopoulos K, et al. Among authors: papadimitriou c. Cancer Genomics Proteomics. 2023 Sep-Oct;20(5):448-455. doi: 10.21873/cgp.20396. Cancer Genomics Proteomics. 2023. PMID: 37643779 Free PMC article.
RediScore: Prospective validation of a pipeline for homologous recombination deficiency analysis.
Tsantikidi A, Papazisis K, Floros T, Gazouli M, Papadopoulou E, Tsaousis G, Nasioulas G, Mester A, Milan KP, Gozman B, Afrasanie V, Stanculeanu DL, Trifanescu O, Pescaru F, Militaru C, Papadimitriou C. Tsantikidi A, et al. Among authors: papadimitriou c. Oncol Lett. 2023 Sep 22;26(5):480. doi: 10.3892/ol.2023.14060. eCollection 2023 Nov. Oncol Lett. 2023. PMID: 37809048 Free PMC article.
Direct comparison of an ultrasensitive real-time PCR assay with droplet digital PCR for the detection of PIK3CA hotspot mutations in primary tumors, plasma cell-free DNA and paired CTC-derived gDNAs.
Smilkou S, Kaklamanis L, Balgouranidou I, Linardou H, Papatheodoridi AM, Zagouri F, Razis E, Kakolyris S, Psyrri A, Papadimitriou C, Markou A, Lianidou E. Smilkou S, et al. Among authors: papadimitriou c. Front Oncol. 2024 Dec 6;14:1435559. doi: 10.3389/fonc.2024.1435559. eCollection 2024. Front Oncol. 2024. PMID: 39711963 Free PMC article.
Molecular Alterations in Paired Epithelial Ovarian Tumors in Patients Treated with Neoadjuvant Chemotherapy.
Nikolaidi A, Papadopoulou E, Haidopoulos D, Liontos M, Fountzilas E, Tsaousis G, Goula K, Tsolaki E, Christopoulou A, Binas I, Stamatopoulou S, Koumarianou A, Karageorgopoulou S, Goussia A, Psyrri A, Papadimitriou C, Gogas H. Nikolaidi A, et al. Among authors: papadimitriou c. Cancers (Basel). 2024 Oct 24;16(21):3580. doi: 10.3390/cancers16213580. Cancers (Basel). 2024. PMID: 39518021 Free PMC article.
ENGOT-en11/GOG-3053/KEYNOTE-B21: a randomised, double-blind, phase III study of pembrolizumab or placebo plus adjuvant chemotherapy with or without radiotherapy in patients with newly diagnosed, high-risk endometrial cancer.
Van Gorp T, Cibula D, Lv W, Backes F, Ortaç F, Hasegawa K, Lindemann K, Savarese A, Laenen A, Kim YM, Bodnar L, Barretina-Ginesta MP, Gilbert L, Pothuri B, Chen X, Flores MB, Levy T, Colombo N, Papadimitriou C, Buchanan T, Hanker LC, Eminowicz G, Rob L, Black D, Lichfield J, Lin G, Orlowski R, Keefe S, Lortholary A, Slomovitz B; ENGOT-en11/GOG-3053/KEYNOTE-B21 investigators. Van Gorp T, et al. Among authors: papadimitriou c. Ann Oncol. 2024 Nov;35(11):968-980. doi: 10.1016/j.annonc.2024.08.2242. Epub 2024 Sep 14. Ann Oncol. 2024. PMID: 39284383 Free article. Clinical Trial.
ENGOT-EN20/GOG-3083/XPORT-EC-042 - A phase III, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma: rationale, methods, and trial design.
Vergote I, Perez Fidalgo A, Valabrega G, Monk BJ, Herzog T, Cibula D, Colombo N, Pothuri B, Sehouli J, Korach J, Barlin J, Papadimitriou CA, van Gorp T, Richardson D, McCarthy M, Antill Y, Mirza MR, Li K, Kalyanapu P, Slomovitz B, Coleman RL. Vergote I, et al. Among authors: papadimitriou ca. Int J Gynecol Cancer. 2024 Aug 5;34(8):1283-1289. doi: 10.1136/ijgc-2024-005412. Int J Gynecol Cancer. 2024. PMID: 38627035 Free PMC article. Clinical Trial.
491 results